Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton May 15, 2021 8:54am
203 Views
Post# 33209562

RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down

RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down
StockingUp21 wrote:

I think everyone agree need for nasdaq. 
 

but not option now. Market cap lower than IPO, dilute shareholder over and over. Reverse split for nasdaq, then dilute by 30% and no longer qualify.

 

 

LosAngelesDave wrote: Webster defines backwater exchange - see TSX.   You have 2 biotechs over 1b cap, Tril and Aup.  Hence the backwater designation.  Synonym - see janky, minor, wannabe, #wanttobeusa

 

 



Perhaps expand your intelligence, or at least make an effort to understand what exactly is going on. The same, uninformed rhetoric. " Dilution, dilution, dilution". 
This is a junior Canadian Biotech company. From zero to phase lll.
Do you really not understand the necessity of those equity raises?
Instead of continuing to repeat the same, useless commentary, why not provide an idea, or suggestion as to how you think they should have proceeded, how exactly do you expect that they should have gotten to this point? Were you going to lend them the money?

It's a very simple question that I have yet to hear a reasonable answer to.
What was the alterntive to the equity raises? keeping in mind they needed the money.
What do you suggest they should have done instead?

This is another example of what I stated in my previous post.
One track, uneducated minds, focused solely on the stock price, without accounting for the necessary processes for the company to achieve it's goal. 

<< Previous
Bullboard Posts
Next >>